Principal Financial Group’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Principal Financial Group’s Portfolio NAVB Stock Details NAVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-1,280	Closed	-$24K	–	2231
2016 Q1	$24K	Hold	1,280	–	–	﹤0.01%	2155
2015 Q4	$34K	Hold	1,280	–	–	﹤0.01%	2170
2015 Q3	$58K	Buy	+1,280	New	+$48.3K	﹤0.01%	2128
2015 Q2	–	Sell	-1,687	Closed	-$54K	–	2240
2015 Q1	$54K	Sell	1,687 -20	-1%	-$677	﹤0.01%	2134
2014 Q4	$65K	Sell	1,707 -40	-2%	-$1.1K	﹤0.01%	2144
2014 Q3	$46K	Hold	1,747	–	–	﹤0.01%	2191
2014 Q2	$52K	Buy	+1,747	New	+$56.5K	﹤0.01%	2233

Other funds holding NAVB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Principal Financial Group's NAVB Position: Q2 2016 in Review

Principal Financial Group sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q2 2016, closing a stake of 1,280 shares — an estimated $24K sold.

Principal Financial Group first reported a position in NAVB in Q2 2014 and held it in 7 quarters. The position peaked at $65K in Q4 2014. 63 funds tracked by Wall St. Rank hold NAVB as of Q2 2016.

Principal Financial Group reported no remaining Navidea Biopharmaceuticals Inc. position as of Q2 2016 after selling out during the quarter.
Principal Financial Group sold 1,280 Navidea Biopharmaceuticals Inc. shares in Q2 2016, an estimated $24K.
Principal Financial Group first reported a position in Navidea Biopharmaceuticals Inc. in Q2 2014 and held it in 7 quarters.
Principal Financial Group's Navidea Biopharmaceuticals Inc. position peaked at $65K in Q4 2014.
63 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q2 2016.

Based on Principal Financial Group's 13F filing for Q2 2016, filed 9 Aug 2016.